Core Insights - Inspira Technologies announced a strategic commercial showcase of its FDA-cleared INSPIRA™ ART100 system at the AmSECT 64th International Conference, scheduled for March 25–29, 2026, in Austin, Texas [1][4] Group 1: Commercial Strategy - The showcase aims to engage directly with decision-makers in hospitals, enhancing the company's U.S. commercial strategy and expanding clinical partnerships and distribution [3][7] - The ART100 system has received FDA 510(k) clearance, validating its readiness for clinical integration in cardiopulmonary bypass procedures [7] Group 2: Product Overview - The INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., serving as a foundation for the development of the next-generation INSPIRA ART500 system [5] - The company is also advancing the HYLA™ blood sensor platform, which offers continuous, non-invasive monitoring [5] Group 3: Industry Context - The AmSECT International Conference is a key global event for perfusion technology, featuring cutting-edge medical technologies and expert-led sessions [4]

Core Viewpoint - Medtronic reported a decline in profit during its fiscal third quarter due to rising costs and increased investments in the business, which countered the effects of higher revenue [1] Financial Performance - The company experienced a profit decrease in the fiscal third quarter, attributed to escalating costs and strategic investments [1] - Higher revenue was noted, but it was not sufficient to offset the increased expenses [1]

Medtronic plc (MDT) shares were down more than 5% in pre-market trading on Tuesday after the healthcare company reported lower third-quarter profit, primarily due to higher expenses.Net income fell to $1.143 billion, or $0.89 per share, from $1.294 billion, or $1.01 per share a year earlier. Adjusted earnings, which exclude one-time items, came in at $1.750 billion, or $1.36 per share.Operating profit decreased to $1.464 billion from $1.646 billion last year.The company's revenue for the period rose 8.7% t ...

Group 1 - Activist investor Jana Partners has acquired a stake in Fiserv and is urging the company to take actions to improve its declining share price [1] - Fiserv's shares increased by 6.5% in premarket trading following the news [1] - The company's stock has experienced a significant decline, dropping over 67% in 2025 [1]

Medtronic says it expects to take a $185 million hit from tariffs in the fiscal year. ...

Market Overview - U.S. stock futures were slightly down as markets reopened, reflecting cautious sentiment among traders after recent volatility in the tech sector related to AI [1] - Bank of America's monthly global fund manager survey indicates an "uber-bullish" sentiment among investors regarding the economy and earnings for the year, despite concerns over potential overspending on AI infrastructure [1] Economic Indicators - Japan's GDP growth for Q4 was reported at an annualized 0.2%, significantly below the forecasted 1.6% gain, impacting the yen which eased 0.4% against the dollar [1] - In the UK, unemployment rose to 5.2%, the highest level in over ten years excluding the pandemic, leading to speculation of a potential interest rate cut by the Bank of England [1] Corporate Earnings - Walmart has joined the trillion-dollar club of company valuations, now ranking as the 12th most valuable publicly listed company globally [1] - Medtronic and Palo Alto Networks are among the companies set to report earnings this week, with Medtronic already beating quarterly profit estimates due to strong demand for heart devices [2]

Group 1: Danaher and Masimo Acquisition - Danaher (DHR) is nearing a $10 billion acquisition of medical technology company Masimo (MASI), which represents a premium to Masimo's nearly $7 billion market capitalization as of last Friday's close [3][4] - The acquisition would be Danaher's largest since its $21.4 billion takeover of Cytiva in 2020 [5] - Masimo's stock has increased by 32% in premarket trading, despite a 27% decline over the past year [3][5] Group 2: Norwegian Cruise Line and Elliott Investment Management - Elliott Investment Management has acquired over a 10% stake in Norwegian Cruise Line Holdings (NCLH) to advocate for operational and strategic changes [5][6] - Norwegian Cruise Line's shares have decreased nearly 4% year-to-date, underperforming competitors like Carnival (CCL) and Royal Caribbean (RCL) [6] Group 3: Costco Lawsuit - Costco (COST) is facing a class action lawsuit alleging salmonella contamination at its Nebraska chicken processing plant [8] - The lawsuit claims that Costco's failure to control salmonella poses a danger to consumers and violates their trust [8] - Costco reported that its $4.99 rotisserie chicken sales exceeded 157 million worldwide in 2025 [9]

Core Viewpoint - Teleflex Incorporated will host a conference call on February 26, 2026, to discuss its fourth quarter 2025 financial results and provide an operational update [1] Company Information - Teleflex is a global provider of medical technologies focused on improving health and quality of life [1] - The company aims to become the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [1] - Teleflex's product brands include Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™, and Weck™, all united by a common purpose [1] Conference Call Details - The conference call is scheduled for 8:00 a.m. Eastern Time on February 26, 2026 [1] - Participants can pre-register for the call through a provided link and access it via a live audio webcast on the company's website [1] - An audio replay will be available starting at 11:00 a.m. Eastern Time on the same day, accessible through the Teleflex website or by telephone [1]

Core Viewpoint - The medical-device maker is anticipated to function as an independent entity within Danaher's Diagnostics segment [1] Group 1 - The company will operate as a stand-alone business, indicating a strategic focus on its specific market segment [1]

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers   FY26 Q3 revenue: $9.02 billion 8.7% growth year over year   Cardiovascular revenue: $3.46 billion Nearly 14% growth year over year   Diabetes revenue: $796 million Nearly 15% growth year over year Medtronic said Tuesday that a surgeon completed the first U.S. procedure for its Hugo robotic surgery system, shortly after the company received ...